This is a translation of the Swedish initiation of coverage from the 28th of June 2018. We are initiating coverage of Karolinska Development, the only listed Nordic investment company with a pure focus on the life science sector. The portfolio companies are expected to have a significant news flow in the next 12 months, where five pharmaceutical development projects will present data from on-going Phase II studies. We believe that the studies will provide important indications of the pharmaceutical candidates’ effect in humans and strengthen the outlooks to deliver exits.